Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
A 47-year-old woman was referred to Princess Margaret Cancer Centre, Toronto, Canada, in November 2016, with abdominal pain, distension, and weight loss. Baseline serum Ca125 was 1615 U/mL, and prior cytological analysis of ascitic fluid in October 2016 confirmed a diagnosis of high grade serous carcinoma, likely ovarian origin. Computed tomography showed omental caking with peritoneal carcinomatosis, ovarian masses, and pelvic, para-aortic, and ileocolic lymphadenopathy. Primary debulking surgery in December 2016 was attempted but aborted due to the extent of disease intraoperatively, and instead she underwent omentectomy to confirm the diagnosis.
Infiltrative nodules were comprised of pleomorphic cells with high grade nuclear atypia and abundant mitoses, forming papillary architecture and slit-like spaces ( Figure 1 ). Necrosis was readily identified. The immunohistochemical panel ( Figure 2 ) shows positive staining for PAX-8, p16, WT-1, and overexpression of p53, and weakly patchy for estrogen and progesterone receptors. Taken together, the morphology and immunohistochemical pattern is consistent with high grade serous carcinoma, likely from tubal ovarian origin.
Subsequently, she received four cycles of neoadjuvant carboplatin and paclitaxel with good radiographic response. She then underwent total hysterectomy, bilateral salpingo-oophorectomy, and lysis of adhesions in March 2017, and was noted to have a complete response intraoperatively, with no residual disease visible at the end of surgery. The pathology specimen revealed no evidence of carcinoma. She underwent two further cycles of adjuvant chemotherapy, completed in May 2017. She also underwent germline testing using a multi-gene next generation sequencing panel (23 genes) and was found to harbor germline BRCA1 mutation c.1217delA, p.(Asn406Metfs*4), for which genetic counselors were consulted. Her family history was significant for two maternal aunts with ovarian cancer, and she had a background history of viral cardiomyopathy with mildly reduced left ventricular ejection fraction.
After a platinum free interval of 12 months, she presented with headaches and unsteady gait. Magnetic resonance imaging (MRI) of the brain demonstrated intracranial recurrence with right frontal lobe and left cerebellar metastases measuring 10 mm each. Ca125 was 22 kU/L, and computed tomography restaging was unremarkable, aside from borderline enlarged axillary lymph nodes bilaterally.
Dr Shultz: Can You Describe the Management Considerations for Intracranial Metastases in High Grade Serous Ovarian Cancer?
Brain metastases are a rare manifestation of ovarian high grade serous carcinoma, occurring in <2% of patients. 1 Evidence regarding optimal management for brain metastases in ovarian high grade serous carcinoma remains limited due to its rarity. Like most carcinomas, treatment usually includes radiotherapy in addition to systemic therapy. Surgical management is often reserved for larger, symptomatic lesions, or when a pathologic specimen is required.2 Such multimodality approaches produce long term survival in selected cases. 2 Stereotactic radiosurgery is the standard of care for patients with less than four lesions as it decreases the risk of cognitive toxicity compared with whole brain radiotherapy. 3 When surgery is required, stereotactic radiosurgery targeting the surgical cavity similarly decreases the risk of toxicity compared with whole brain radiotherapy.
Our patient underwent stereotactic radiosurgery to a dose of 21 Gy, targeting both intracranial lesions, followed by four cycles of platinum and gemcitabine, switching from carboplatin to cisplatin for the final two cycles due to hypersensitivity. She was commenced on maintenance olaparib, a poly ADP-ribose polymerase inhibitor, in November 2018. Furthermore, her archival surgical specimens were included in a molecular profiling study (NCT02906943) of 555 genes, where 15 variants were detected, including likely oncogenic variants in BRCA1, SMAD4, and TP53.
Dr Rouzbahman and Dr Stockley: Could You Please Discuss Any Known Pathological Mechanisms Behind Development of Brain Metastases in Ovarian Cancer?
To date, studies focusing on pathological markers predictive for development of brain metastases in ovarian high grade serous carcinoma have been very limited. Although the main route of spread in high grade serous carcinoma appears to be through peritoneal surfaces, occasionally hematogenous spread is encountered, usually to the liver or lung. Metastases to the central nervous system are quite uncommon and usually a late manifestation but rare reports of brain metastasis as the initial presentation of high grade serous carcinoma are present. 2 Recent reviews on genomic alterations suggest that the presence of BRCA mutations or variants in other DNA repair pathways, such as ATM or CHEK2, increases the likelihood of developing brain metastases. 1 4 Choi et al demonstrated on two patients that higher mutational burden and programmed cell death ligand-1 IHC expression was seen on brain metastatic tissue, but no single genomic alteration was attributable. 5 Stasenko et al demonstrated that in 63 patients with BRCA mutations, overall survival was prolonged compared with BRCA wild-type patients but this finding became insignificant on controlling for extracranial disease, either due to the sensitivity of BRCA mutated cells to platinum or due to small sample size. 6 Additionally, one study of 100 gynecologic cancer patients also revealed that vascular endothelial growth factor-A, which is a pro-angiogenic factor targeted by bevacizumab, was expressed at slightly higher levels in metastatic brain tissue than primary tumor. 7 It is possible that due to the increased number of available treatment options and subsequent prolonged survival times, that the number of patients presenting with brain metastases will increase due to tumor heterogeneity and isolation of resistant clones. 8 Involving these patients in biomarker studies, particular where primary and metastatic tissue is available for analysis, remains of the utmost importance to achieve a better understanding behind the pathogenesis of brain metastasis.
Dr Oza: Please Discuss the Use of Poly ADP-ribose Polymerase Inhibitors in Ovarian Cancer with Brain Metastases
Poly ADP-ribose polymerase inhibitors used as maintenance therapy following response to platinum based chemotherapy in firstline and recurrent ovarian high grade serous carcinoma settings has become standard of care in those with BRCA mutations, with significant survival benefit and manageable toxicity rates, with no significant effects on quality of life. 9 Systemic therapy in patients with brain metastases has historically posed a significant management challenge due to poor drug uptake across the blood–brain barrier, despite the hypothesis that the barrier is disrupted in the presence of intracranial metastases. In the preclinical setting, pharmacokinetic studies demonstrated antitumor activity in xenograft BRCA mutated tumors with therapeutic tumor growth inhibition to niraparib to a greater degree than olaparib. 10 Mouse xenograft pharmacokinetic studies also showed accumulation and retention of rucaparib in tumor cells, but this was at a much lower level in brain tissue. 11 One of the earliest observations of efficacy of poly ADP-ribose polymerase inhibitors in patients with brain metastases was reported by Professor Stan Kaye, who reported clinical activity and disease regression in a woman with endometrioid endometrial cancer and brain metastases in one of the earliest phase I patients being treated with olaparib. 12 There have since been an increasing number of high grade serous carcinoma case reports documenting the clinical efficacy of this drug class in inducing prolonged intracranial tumor responses 13–15 ; however, none of the published prospective poly ADP-ribose polymerase inhibitor studies in high grade serous carcinoma analyzed efficacy in patients with brain metastases, despite those with treated, stable brain metastases being eligible. Furthermore, those with symptomatic or untreated brain metastases were excluded from these studies. Currently, to my knowledge, there are no trials in progress assessing the activity of poly ADP-ribose polymerase inhibitors in ovarian cancer with brain metastases.
The activity of poly ADP-ribose polymerase inhibitors has also been assessed in other tumor sites. In breast cancer, where brain metastases are a more common occurrence, the phase III EMBRACA trial (A Study Evaluating Talazoparib (BMN 673), a PARPInhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCAMutation) looking at talazoparib in BRCA mutated metastatic disease, detected a progression free survival benefit on subgroup analysis of 63 patients with brain metastases compared with chemotherapy alone (hazard ratio 0.32, 95% confidence interval 0.15 to 0.68), implying clinical activity. 16 In primary central nervous system tumors, the OPARATIC phase I trial demonstrated that after receiving olaparib with temozolomide, 100% of surgical resection specimens in 27 patients contained radiosensitizing concentrations of olaparib. 17 Although data from these studies are limited and have small sample sizes, they provide encouraging signals of the potential clinical utility of poly ADP-ribose polymerase inhibitors in controlling intracranial malignancies.
In October 2019, both intracranial lesions demonstrated progression on surveillance brain MRI despite stable extracranial disease. Her brain metastases were targeted again with stereotactic radiosurgery, 21 Gy in three fractions, with a 3 week break in olaparib. In January 2020, the patient developed symptoms consistent with increased intracranial pressure, and surveillance brain MRI revealed increased vasogenic edema associated with her known metastases, requiring a several weeks course of dexamethasone. Due to repeated prolonged courses of steroids, she developed steroid induced diabetes mellitus. She also experienced a transient, acute rise in liver transaminases of unclear etiology requiring a 2 week break in olaparib. In June 2020, repeat imaging was obtained for surveillance, demonstrating no recurrent disease extracranially. An MRI was performed for surveillance, showing enlargement of a right frontal lobe lesion ( Figure 3 ).
Axial T1 weighted images post-contrast demonstrated a right frontal lobe, subcortical white matter, and ring enhancing lesion with central necrosis ( Figure 3A ). Fluid attenuated inversion recovery imaging demonstrated surrounding edema but no significant mass effect ( Figure 3B ). In the posterior fossa there was a left cerebellar metastatic lesion demonstrating peripheral enhancement post-contrast with central necrosis ( Figure 3C ). There was surrounding fluid attenuated inversion recovery hyperintensity well seen on Figure 3D with mild mass effect on the cerebellar folia.
She was asymptomatic at the time. Following multidisciplinary discussion, she underwent craniotomy and laser interstitial thermotherapy ablation in late June 2020 and is pending recommencement of olaparib.
Dr Oza: What is the Rationale for Continuing Poly ADP-ribose Polymerase Inhibition After Local Therapy in These Patients?
Despite the aforementioned reports, there is currently no literature describing whether poly ADP-ribose polymerase inhibitors should continue after local therapy for intracranial progression in the absence of extracranial disease. This case described asymptomatic intracranial progression without extracranial recurrence while on olaparib on multiple occasions, and following local therapy with either radiation or surgery, olaparib was continued. This practice of using targeted therapies beyond intracranial progression can be seen in other malignancies, such as non-small cell lung cancer, where epidermal growth factor receptor or anaplastic lymphoma kinase mutated tumors receive ongoing systemic therapy following local ablative treatments. 18 Furthermore, consideration should be given to continuing poly ADP-ribose polymerase inhibitors beyond localized disease control in ovarian high grade serous carcinoma extracranial oligometastatic progression, given that progression in this context likely occurs within the context of clonal heterogeneity. Local treatment such as stereotactic body radiotherapy has been shown to achieve good local control, and several large poly ADP-ribose polymerase inhibitor studies have previously allowed continuation beyond progression. 9 19 These clinical conundrums are highly individualized and require further evaluation in future studies.
One could argue that given the multiple instances of intracranial progression, that olaparib was failing to achieve disease control, which may be due to other factors, such as clonal heterogeneity. However, recommencement of chemotherapy is a less attractive option due to poor blood–brain barrier penetrance and risk of toxicity in the absence of extracranial disease. Another option would be to cease olaparib and continue on surveillance alone; however, given the presence of a BRCA mutation in the context of high grade serous carcinoma histology, there is concern that disease progression would occur rapidly, which could potentially be highly morbid if presenting as new intracranial metastases with vasogenic edema, or alternatively as widespread systemic disease. It is also possible that reversion mutations, or other molecular mechanisms pertaining to poly ADP-ribose polymerase inhibitor resistance, could be present given the duration of treatment. However, unfortunately, no biopsy was obtained at the time of craniotomy, and given the risk of extracranial disease progression, this would not alter management. A considered approach needs to be taken in managing patients in these situations, and transparent discussions should be had with each patient to ensure the optimal individualized management strategy.
This case describes a woman with ovarian high grade serous carcinoma diagnosed with brain metastases on platinum sensitive recurrence, for which following stereotactic radiosurgery and platinum based chemotherapy she was commenced on olaparib maintenance. She harbored a germline BRCA1 mutation. Due to the development of intracranial progression in the absence of extracranial disease, she underwent further radiation on a number of occasions and continued olaparib with manageable toxicity. A summary of her treatment history is displayed in Figure 4.
In conclusion, this case highlights the complex considerations associated with multimodal treatment in an ovarian high grade serous carcinoma subpopulation with intracranial metastases. Due to the rarity of brain metastases in this population, the evidence remains sparse and a number of questions have been raised surrounding the appropriateness of continuing poly ADP-ribose polymerase inhibitors in isolated intracranial progression. Standard practice guidelines for treatment of brain metastases in ovarian high grade serous carcinoma are yet to be clearly defined, and certainly the gynecologic oncology community will require increasing documentation of experience with poly ADP-ribose polymerase inhibitors in patients with brain metastases. With the increase in numbers of treatment options, identification of novel predictive markers and prolonged survival times, unusual manifestations of ovarian high grade serous carcinoma, such as brain metastases, are likely to become increasingly common. Prospective studies of diagnostic and treatment approaches will be necessary to understand the pathogenesis of brain metastasis and consequently identify optimal management strategies for these patients.
The authors wish to acknowledge Katherine Karakasis and Dr Eric Chen for technical editing and review of the manuscript.
Twitter @LKasherman, @AinhoaMada
Contributors Presenters: LK and AM. Pathologist: MR. Radiologist: KM. Discussants: DS, TS, and AMO.
Funding The Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario; grant Nos P.OCT.051 and P.AO.075.
Competing interests AMO is on the steering committee of GlaxoSmithKline, AstraZeneca, Clovis, Tesaro and Merck (uncompensated), and is PI on clinical trials for AstraZeneca, GlaxoSmithKline, and Clovis.
Patient consent for publication Obtained.
Provenance and peer review Commissioned; internally peer reviewed.